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The transcription of the human immunodeficiency virus type 1 (HIV- 1) is under the control of cellular
proteins that bind to the viral long terminal repeat (LTR). Among the protein-binding regions of the HIV-
LTR is the transcription-enhancer region. We show that at least one inducible, Cl, and one constitutive,
C2, protein can bind to the HIV enhancer in Jurkat cells. The two proteins differ in their surface charge, since
they are separable by anion-exchange chromatography. Bivalent cations such as Mg2" and Zn2+ differentially
affect their binding to oligonucleotides which contain the HIV-enhancer domain. Both Cl and C2 proteins
also bind to a similar sequence found in the interleukin-2-receptor a-subunit enhancer. The inducible Cl
protein was partially purified by three chromatographic steps and characterized by u.v. cross-linking as a
47 kDa protein.
INTRODUCTION
Human immunodeficiency virus 1 (HIV- 1) is the
etiological agent of AIDS (acquired immunodeficiency
syndrome) [1,2]. The virus typically infects cells ex-
pressing the CD4 receptor [3,4]. However, the virus is
able to express its gene products even when transfected
into cells that do not express the CD4 receptor, such as
HeLa cells [5]. These observations imply that HIV is able
to use host-cell transcriptional factors common to many
cell types for its transcriptional regulation.
Deletion analysis ofchloramphenicol acetyltransferase
constructs (CAT assays) and DNAase footprinting assays
of the HIV long terminal repeat (LTR) have revealed
that at least five distinct regions are involved in the
regulation of the transcription of the viral genes by
interacting with cellular proteins [6]. Among these
regions, a negative regulatory element (- 173 to - 159)
and a positive regulatory element or enhancer (-104 to
-78) have been identified [6-8]. The enhancer element
is composed of two direct repeats of the sequence
GGGACTTTCC [8,9]. This sequence is identical with
the K-light-chain-enhancer sequence or KB site, except
that the sequence is not repeated [10]. The K-light-chain-
enhancer site is bound by a constitutively expressed
protein, NF-KB, in mature B-cells. In pre-B-cells, NF-KB
is induced by lipopolysaccharide [10]. NF-KB was recently
purified from bovine spleen and shown to be a 42-
44 kDa protein [1 1]. Furthermore, Nabel & Baltimore [9]
showed that phorbol ester plus mitogen induced a protein
that is specific to a human T-cell line (Jurkat) and binds
to the HIV enhancer element. In their original report
those authors postulated that the HIV-enhancer-specific
binding protein in Jurkat cells is identical with B-cell NF-
KB. Stimulation of Jurkat cells with lectin and phorbol
esters induces the expression of both interleukin-2 (IL2)
and its receptor a-subunit (IL2Ra). Purified NF-cB
binds to both IL2 and IL2Ra enhancer domains [11].
However, another protein, HIVEN 86A, characterized in
the same cells, was able to bind both the HIV enhancer
element [12] and the IL2Ra enhancer [13]. Two other
groups have purified HIV enhancer-binding proteins
from phorbol-ester-treated HeLa cells [14] and the
Namalwa B-cell line [15]. The protein purified from
HeLa-cell extracts had an apparent Mr of 55000-60000,
whereas the Mr of the protein from the Namalwa cells
was reported to be 51000. Therefore both lymphoid and
non-lymphoid cells express proteins capable of
specifically binding to the HIV enhancer domain, but
only mature B-cells express the NF-KB protein
constitutively. The relationship between NF-KB and
other HIV enhancer-binding proteins is not yet
elucidated.
Here we show that stimulation of Jurkat cells with
phorbol 1 2-myristate 13-acetate (PMA) and
phytohaemagglutinin (PHA) induces at least two proteins
capable of binding specifically to the HIV enhancer
element. We describe the separation of these proteins
and the partial purification and characterization of the
major 47 kDa protein.
EXPERIMENTAL
Cell culture
The Jurkat T-cell line was cultured in RPMI 1640
medium supplemented with 100 (v/v) fetal-calf serum,
glutamine and penicillin/streptomycin. The cells were
stimulated for 3 h with 2 ,tg of PHA (Burroughs
Wellcome) and 50 ng of PMA (Sigma).
Protein extraction
Whole cell extracts were obtained as described pre-
viously [16]. The final protein extract contained 5-25 mg
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of protein/ml of buffer A50 [50 mM-(NH4)2SO4/1 mM-
EDTA/10% (v/v) glycerol/I mM-dithiothreitol (DTT)/
20 mM-Tris/HCl (pH 8.0)/i mM-PMSF]. The extraction
procedure included an (NH4)2S04 precipitation at 50%
saturation. Cell extracts were stored at -80 'C.
Oligonucleotides and gel-retardation assay
Two synthetic double-stranded oligonucleotides were
used as probes for detection of the HIV enhancer-
binding proteins. A 31-mer oligonucleotide or 'Tandemr',
which contains the two direct repeats ofthe HIV enhancer
sequence from the position - 107 to -80 [6] (5'-
ACAAGGGACTTTCCGCTGGGGACTTTCCAGG-
3'), and a 16-mer oligonucleotide or 'Mono', containing
only the 5' site from the position - 107 to -92. Two
other double-stranded oligonucleotides were also
synthesized: a 16-mer containing the sequence of the
IL2Ra promoter from the position -270 to -255 [17]
(5'-GCAGGGAATCTCCCT-3') and a 33-mer
oligonucleotide containing the cyclic AMP-responsive
element (CRE) of the human pro-enkephalin from the
position - 108 to -76 [18] (5'-GGGCTGGCGTAGG-
GCCTGCGTCAGCTGCAGCCC-3'). In the u.v. cross-
linking experiments, an oligonucleotide containing the
API/c-Jun binding site [19] was also used (5'-
GATCCGGCTGACTCATG-3'). The oligonucleotide
probes were end-labelled with phage-T4 kinase.
The gel-retardation assays were performed as follows:
5 pul of protein solution (0.4-200 #tg) was incubated onice in a final volume of 20,1l of 20 mM-Tris/HCI
(pH 8.0)/ 100% glycerol/ I mM-DTT / 60 mM-KCl/ poly-
(dl dC) (2,ag). After 15 min incubation, the 32P-end-
labelled oligonucleotide was added (100000-500000
c.p.m.; 0.1 ng) and the binding reaction was allowed to
proceed at room temperature for 15 min. The bound
oligonucleotide was separated from the free by electro-
phoresis on a 60% (w/v) polyacrylamide gel in 0.25X
TBE [22.5 mM-Tris/borate (pH 8.0)/0.5 mM-EDTA]. The
specific activity was determined as described by Yano
et al. [20], except that the radioactivity of the bands
was counted by the Cerenkov rather than the liquid-
scintillation method, and the control DNA was the
unbound free oligonucleotide. The specific activity is
expressed as pg of retarded radiolabelled probe/mg of
protein. Total activity was obtained by multiplying the
specific activity by the total amount of protein and is
therefore also expressed in pg.
H.p.l.c. and affinity-chromatographic fractionation
The whole-cell extract from 25 x 109 cells (400 mg of
protein) was diluted 3-fold with the column buffer
[20 mM-Tris/HCl (pH 8.0)/i mM-EDTA] and loaded on
to a Bio-Gel TSK-DEAE-5-PW column at a flow rate of
5 ml/min. The column was washed with twice its volume
of column buffer, and the bound proteins were eluted
with a linear gradient ofKCI (0-0.5 M). The S ml fractions
were dialysed against the A50 buffer and tested for their
HIV enhancer-binding activity by the DNA gel-retar-
dation assay. The fractions containing the PMA + PHA-
induced proteins were pooled (pool 1; see Fig. 3 below)
and further fractionated by affinity chromatography by
using a trimeric repeat of the mono oligonucleotide (a
48-mer) covalently bound to a CNBr-activated Sepharose
(Pharmacia) as described in [21]. The density of the
oligonucleotide was approx. 140,ug/g of dry gel. The
proteins were loaded at a rate of 0.5 ml/min. The
unbound material was washed out with 2.5 column
volumes of the A50 buffer. The bound proteins were
eluted in 2 ml fractions by a discontinuous gradient of
KCI (0.2, 0.5 and 1.0 M) in the presence of a 0.05%
Nonidet P40. After dialysing the fractions against the
A50 buffer, the DNA-binding activity was assayed by the
DNA gel-retardation assay. The active dialysed fractions
were pooled, and the affinity chromatography was re-
peated a second time.
U.v. cross-linking
The probe used for the u.v. cross-linking experiment
was prepared by following the instructions of the manu-
facturer (Boehringer-Mannheim); the Tandem single-
stranded oligonucleotide was added to the Boehringer-
Mannheim random primed DNA labelling kit mixture.
A 100 1tCi portion of[32P]dCTP and 0.5 nmol ofBrdUTP
were added.to the reaction mixture. After 30 min in-
cubation at 37 °C, 0.5 nmol of dCTP were added. The
labelled probe was purified from the free nucleotides by
two passages through Sepharose G-25. Its radioactivity
averaged 500000 c.p.m./,ul. The u.v. cross-linking of
proteins with the 32P-labelled BrdUr-substituted Tandem
oligonucleotide was performed as described [22], except
that after irradiation the samples were immediately
boiled in 2.5% SDS/1 mM-EDTA/20 Qo glycerol/i 00 2-
mercaptoethanol. The electrophoretic separation was
performed on 10%-polyacrylamide gels as described by
Porzio & Pearson [23].
RESULTS
Induction of HIV enhancer-binding proteins
We first examined the capacity of proteins extracted
from Jurkat cells to bind to the synthetic oligonucleotides
which represented either a single copy (Mono) or two
copies (Tandem) of the KB site of the HIV enhancer
domain. Both oligonucleotides formed two protein-
DNA complexes, Cl and C2, with distinct electro-
phoretic mobilities (Fig. 1). The Cl complex was greatly
increased by the stimulation of Jurkat cells by PMA and
PHA. This is in agreement with previously described
induction of HIV enhancer-binding proteins in Jurkat
cells by Nabel & Baltimore [9]. In their study the
radiolabelled probe used was much larger (90 bp)
compared with the Tandem oligonucleotide and included
an upstream 50 bp extension. The single KB site (Mono)-
retarded migration was undistinguishable from.that of
the Tandem, suggesting that the two oligonucleotides
bind the same proteins. It is also very likely that the two
potential KB sites in the Tandem oligonucleotide cannot
bind proteins simultaneously, since no slower migrating
complex than that of Cl was seen with the Tandem.
However the length of the probe is critical, since we did
not see any retardation ofMono oligonucleotides shorter
than 14 bp. This observation may be attributable to the
high dissociation rate of the protein-DNA complex with
short DNA probes. The Cl complex was not affected by
cycloheximide and actinomycin D treatment of Jurkat
cells, suggesting that its induction is not due to protein
synthesis de novo (results not shown). The C2-complex in
contrast with the Cl-complex proteins appear to be
constitutively active in Jurkat cells (Fig. 1).
Ionic requirement of the Cl and C2 complexes
We further characterized the DNA binding of Cl and
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Fig. 1. Induction of HIV enhancer-binding proteins in Jurkat
cells
Gel retardation of 32P-labelled Mono and Tandem
oligonucleotides (Oligo) by proteins (15 ,ug) extracted from
PMA + PHA-stimulated (+) or unstimulated (-) Jurkat
cells was performed as described in the Experimental
section. Cl and C2 indicate the migration of the oligo-
nucleotides complexed to the proteins. 'Free' refers to
the free oligonucleotides.
C2 by studying the effect of ions on their interaction with
the mono probe. Bivalent cations such as Zn2+, Ca2+ and
Mg2+ had differential effects on the stability ofCl and C2
complexes. At 1 mM, Zn2+ inhibited the formation of the
Cl complex (Fig. 1, lane 2), whereas Mg2+ and Ca2+ did
not (Fig. 2, lanes 5 and 8). At higher Zn2+ concentrations
(2 and 5 mM) Cl complex was dissociated, whereas
the C2 complex was greatly augmented (Fig. 2, lanes 3
and 4). At the same concentrations Ca2+ had no effect on
the stability of either Cl or C2, whereas Mg2+ (5 mM) had
a dissociating effect on the Cl complex without affecting
the C2 complex (Fig. 2). EDTA (10 mM) had no effect on
the Cl complex, favoured partial dissociation of C2
complex (Fig. 2, lane 11) and efficiently abolished the
dissociating effect of Mg2+ on the Cl complex (results
not shown). Cl and C2 also differed in their sensitivity to
high ionic strength, since Cl was more easily dissociated
by 0.4 M-KCl than was C2 (Fig. 2, lane 12). Therefore it
is possible to favour selectively the binding of either Cl
or C2 proteins to the HIV enhancer by manipulating the
ionic composition of the reaction medium.
Isolation of the Cl-complex protein
In order to isolate the inducible Cl-complex proteins
we performed the fractionation and oligonucleotide-
binding assays in the absence of Mg2+ ions. The first
chromatographic fractionation was performed with
DEAE-5PW h.p.l.c. About 70% of the loaded proteins
did bind to the column (Fig. 3b). The oligonucleotide-
binding activity was found exclusively in the KCl-eluted
fractions, suggesting that all the active proteins bound to
the DEAE (Fig. 3a). The proteins migrating as C2' were
Lane... 1 2 3 4 5 6 7 8 9 10 11 12
C1 --.
C2 -
Free -*
Fig. 2. Ion-dependence of oligonucleotide-protein interaction
Gel retardation of the 32P-labelled mono oligonucleotide was performed with 15 ,ug of stimulated Jurkat-cell extracts, either
under the standard conditions described in the Experimental section (lane 1) or in the presence of 1, 2 or 5 mM-ZnSO4 (lanes
2, 3 and 4); 1, 2 or 5 mM-MgCl2 (lanes 5, 6 and 7); 1, 2 or 5 mM-CaCl2 (lanes 8, 9 and 10); 10 mM-EDTA (lane 1 1) and 40 mM-
KCI (lane 12). 'Free' refers to the free oligonucleotides. 'Cl' and 'C2' refer to the complexes.
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Fig. 3. Fractionation of proteins extracted from stimulated Jurkat cells by DEAE-cellulose h.p.l.c.
(a) shows the gel retardation of 32P-labelled Mono oligonucleotide by the DEAE h.p.l.c. fractions. The migration of the
oligonucleotide retarded by the initial extract is shown in lane I. Cl and C2 indicate the migration of the oligonucleotide in the
presence of fractions from respectively pools 1 and 3, whereas C2' indicates the faster-migrating complexes from pool 2. (b)
Represents the recording of the protein elution from the column by absorbance at 280 nm. The flow-through (FT) and the
washings (WI and W2) were collected separately.
eluted with 0.15 M-KCI and pooled (pool 2; Fig. 3a). The
Cl proteins were eluted at higher salt concentrations
(0.22-0.25 M-KCI) (pool 1). A third pool (pool 3, fractions
30-33), contained both the Cl and C2 proteins eluted
with 0.25-0.3 M-KCI. The C2 and C2' proteins either co-
migrated in the unfractionated extract or one of the two
activities was generated by the fractionation procedure.
Indeed, the fractionation could possibly have eliminated
an inhibitor of one of the two binding activities.
After pooling the fractions containing the same binding
activities, we analysed the specificity of their binding to
the 32P-labelled Mono probe by competition with a 100-
fold excess of unlabelled oligonucleotides (Fig. 4). The
unlabelled Mono and Tandem oligonucleotides competed
for binding to Cl and C2', but not C2. The IL2Ro
enhancer probe partially inhibited the binding of Cl and
C2' and not C2 (lanes 5, 10 and 15). To check the
selectivity of binding of the three pools to the KB site, we
used the CRE oligonucleotide as a competitor, since it
contains a binding site for the cyclic AMP-induced
nuclear proteins. The CRE oligonucleotide has no se-
quence similarity with the KB site (see the Experimental
section). CRE probes did not compete for binding Cl
and C2', but partially inhibited the binding of C2 (lanes
4, 9 and 14). These results indicate that C1 and C2'
binding activities are specific for binding the HIV
enhancer probes, but the C2 protein complex is not. The
IL2Ra enhancer probe sequence is similar to, but not
identical with, the KB site, which may explain why it
appears to have a lower affinity for C1 and C2' binding
activities (see also Fig. 6 below). The sensitivity to Mg2"
of fractionated Cl binding activity remained unchanged
compared with the Cl binding activity from the initial
extract. C2' complex was also inhibited by 5 mM-Mg2",
whereas C2 was not, suggesting that the C2 binding
activity in the initial extract was mainly due to proteins
from pool 3 (results not shown).
The Cl binding activity from pool 1, which represents
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Fig. 4. Gel retardation of 32P-labelled Mono oligonucleotide in the presence of competitor DNA
Lanes 1-5 show the result of the assay performed with fractions from the pool 1. Lanes 6-10 and 13-15 represent respectively
the assay with pools 2 and 3. The assay performed in the absence of competitor DNA is shown in lanes 1, 6 and 11. The other
lanes represent the retardation in the presence of 100-fold excess of Mono (lanes 2, 7 and 12), Tandem (lanes 3, 8, and 13), CRE(lanes 4, 9 and 14) and IL2Ra enhancer (lanes 5, 10 and 15) oligonucleotides. 'Free' refers to the free oligonucleotide.
the major induced proteins, was further purified by two-
step affinity chromatography. The activity was eluted
with 0.5 M-KCl and co-migrated with the Cl complex
from the unfractionated pool 1 (Fig. 5). A single migrat-
ing activity was generated by this chromatographic
step; however, recovery after this step was superior to
that obtained after DEAE h.p.l.c. (see Table 1). One
possible explanation for this enhanced yield is the elimin-
ation of an inhibitor during this chromatographic step.
Similar increases in activity were recently described
during the purification of the NF-KB from bovine spleen
[11] (see the Discussion section). The overall enrichment
after this first affinity chromatography was 800-fold (see
Table 1). The active fractions were pooled and refraction-
ated by the same chromatographic procedure. Cl activity
was eluted in two fractions with 0.5 M-KCI (results not
shown). This second step resulted in a 1000-fold overall
purification (Table 1), but recovery decreased from 70 to
43 % of the initial activity. C2' binding activity from
pool 2 was also analysed by affinity chromatography.
However, the recovery of activity after this step was too
low to allow further analysis.
Molecular-mass analysis of Cl proteins by u.v. cross-
linking
To determine the molecular mass of the Cl proteins,
we loaded the initial extract directly on the affinity-
chromatography column in the presence of 1 mM-EDTA.
The Cl binding activity was eluted with 0.5 M-KCI (results
not shown). This single fractionation step permitted a
200-fold enrichment of the Cl activity. The active
fractions were then u.v.-cross-linked with 32P-labelled
BrdUr-substituted Tandem probe as described in the
Experimental section. Two proteins of 47 kDa (p47) and
60 kDa (p60) were prominently labelled (Fig. 6, lane 1).
The addition of 500-fold molar excess of unlabelled
competitors differentially affected the two proteins
complexed with the oligonucleotide probe. Unlabelled
Tandem probe completely inhibited the labelling of p47
and only partially inhibited p60 complex, whereas two
sequence-unrelated oligonucleotides, corresponding to
the CRE and API binding sites, did not inhibit the
labelling of p47, although they partially inhibited the
labelling of the p60 (Fig. 6, lanes 3 and 5). The IL2Ra
enhancer probe partially inhibited the labelling of both
p47 and p60 (Fig. 6, lane 4). When u.v. cross-linking was
performed with the initial extract, many proteins were
labelled, including p47 and p60 (results not shown). We
also performed u.v. cross-linking of 1000-fold-purified
Cl binding activity by both the DEAE h.p.l.c. and the
two affinity-chromatographic steps (see Table 1). A
labelled protein migrated with an apparent molecular
mass of 40 kDa. This difference in molecular mass is
probably due to partial proteolysis occurring during the
three-step purification. We deduce from the u.v.-cross-
linking data that the protein responsible for Cl complex-
formation has a molecular mass of 47 kDa.
DISCUSSION
In the present study we have shown that several
proteins extracted from mitogen-stimulated Jurkat cells
can interact with the KB sites that are contained in the
HIV enhancer domain. These proteins differ in the extent
of their migration during non-denaturing gel
electrophoresis after binding with oligonucleotides. They
also differ in their ionic requirements for stable in-
teraction with the oligonucleotides. The effect of Mg2"
on Cl and C2 activities is summarized in Table 2. The
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Fig. 5. Affinity chromatography of the pool-1 proteins
The Figure shows the gel retardation of 32P-labelled Mono oligonucleotide by proteins from fractions eluted from the
DNA-Sepharose column. The retardation by the initial extract is shown in lane I. The pool-I lane shows the retardation by
proteins before affinity-chromatographic fractionation. The flow-through (FT) and column washings (WI and W2) correspond
to unbound material. Bound proteins were eluted in ten fractions (lanes 1-10) with increasing concentration of KCI: 0.2 M-KCI
(lanes 1, 2 and 3), 0.5 M-KCl (lanes 4, 5 and 6) and 1 M-KCI (lanes 7, 8, 9 and 10). 'Free' refers to the free oligonucleotide.
Table 1. Isolation of p47 protein
Specific Total
Protein Volume activity* activity Purification Recovery
Step (mg) (ml) (pg/mg) (pg) factor (MO)
Extraction 400 15 38 15200 1 100
DEAE h.p.l.c. 11.5 25 260 2990 6.8 20
First affinity chromatography 0.328 6 32000 10496 842 70
Second affinity chromatography 0.160 4 41000 6560 1078 43
* The specific activity was defined as described in the Experimental section as pg of retarded radiolabelled probe/mg of protein.
negative effect of Mg2+ on the interaction of the inducible
Cl DNA-binding activity suggests a regulatory mech-
anism for this protein, because Mg2+ has been also
shown to inhibit transcription assays in vitro with the SV
40 enhancer which contains the KB site [24]. The in-
hibitory effect of Mg2+ is not understood, but it could
cause conformational changes of DNA-binding proteins.
Using two different chromatographic fractionation
procedures we partially isolated an inducible DNA-
binding activity Cl and identified it as a 47 kDa protein
(p47). The C2' protein(s) were eluted from DEAE at
lower salt molarity than was Cl, but exhibited the same
Mg2+-sensitivity as Cl (Table 2). It is not clear whether
the protein(s) responsible for C2' electrophoretic mobility
are related to p47. C2' could be a proteolytic product of
p47 or it may be a modified form of p47 (perhaps due to
phosphorylation of CI).
The induction of active NF-KB in T-cells has been
attributed to dissociation from a cytoplasmic inhibitor,
IKB [28], which allowed the translocation of NF-KB into
the nucleus and subsequent activation of transcription of
IL2 and IL2Ra genes. P47 also might be associated with
an inhibitor, since its fractionation from the whole-cell
extract by affinity chromatography increased binding
activity (see the Results section, in particular Table 1).
Several cellular and viral genes, including the K light
chain, SV 40, /,-microglobulin and IL2ra, have been
shown to contain KB sites in their regulatory regions
[10,11,13,20]. In HIV-1, SV 40, K light chain and ,-
microglobulin, the KB site was shown to regulate gene
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Fig. 6. SDS/polyacrylamide-gel electrophoresis of u.v.-cross-
linked proteins to 32P-labelied BrdUrd-substituted
Tandem oligonucleotide
Affinity-chromatographically purified fraction (0.4,g) was
incubated with the Tandem oligonucleotide (500000 c.p.m.)
alone (lane 1) or with a 500-fold excess of competitor
DNA: Tandem (lane 2), CRE (lane 3), IL2Ra enhancer
(lane 4) and API (lane 5).
Table 2. Effect of Mg2+ on stability of protein-Tandem
oligonucleotide complexes
The protein-oligonucleotide complexes were analysed by
the gel-retardation assay. The MgCl2 concentration was
5 mM.
PMA + PHA- PMA + PHA- Mg2+-
Stage induced non-induced dissociated
Initial extract C1 C2 C1
DEAE h.p.l.c. Cl C2 Cl
C2' (?) C2'
transcription by interacting with cellular proteins. Some
KB-site-binding proteins were isolated and partially
characterized. For example NF-KB, a 42-44 kDa protein,
was purified from bovine spleen cells [11], HIVEN 86A,
a 86 kDa protein, was found in mitogen-stimulated
Jurkat cells [12], EBP-1, a 55-60 kDa protein, was
purified from phorbol-ester-treated HeLa cells [14], and
H2TF1, a 48 kDa protein, was purified from murine
thymoma cells [20]. NF-KB is constitutively expressed
only in mature B-cells, where it regulates the transcription
of K light chain, but it is also inducible in T-cells, where
it might regulate transcription of IL2 and IL2Ra
[11,13,26,27]. At present we have not identified with
certainty a cellular enhancer for p47, since it binds
IL2Ra enhancer probe with much lower affinity than
HIV-1 enhancer probes, at least in the assays in vitro
used in the present study.
In our experiment we found that p47 differs in size
from the previously described Jurkat-cell HIV enhancer-
binding protein, HIVEN 86A [12], as well as from the
HeLa-cell HIV enhancer-binding protein, EBP-1 [14].
However, its size is comparable with NF-KB isolated
either from bovine spleen cells (42-44 kDa) [11] or a
human B-cell line (51 kDa) [15], as well as with the 48 kDa
H2TF1 or KBFl [20]. It is not clear whether p47, NF-KB
and H2TF1 are products of the same gene with different
post-translational modifications or whether they result
from the expression of different genes. It is not unusual
for several different proteins to recognize the same DNA
sequence. Indeed, the mammalian transcription factor c-
Jun/API, the yeast GCN4 and several other mammalian
and yeast proteins all bind to the same consensus
sequence ATGA(C/G)TCAT (see [25] for review).
H2TF1 and NF-KB differ by their KB-site-binding
characteristics [11,29]. However, the relation between
p47, NF-KB, H2TF1, EDBP-l and HIVEN 86 A is not
clear. In spite of several described differences such as
molecular mass, affinities for KB site and modulation of
the binding to KB site by nucleotides, NF-KB, H2TFl
and p47 could be structurally related. The specificity of
their transcriptional activity could be due to different
post-translational modifications or to interaction with
other, cell or signal, specific proteins.
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